Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Outlook 2025 – Insights for Executive and Strategic Planning
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Grown from 2024 to 2025?
The market size for therapeutics treating attention deficit hyperactivity disorder (ADHD) has seen robust growth in the past few years. A rise from $13.21 billion in 2024 to $14.1 billion in 2025, with a compound annual growth rate (CAGR) of 6.7% is predicted. The previous growth can be credited to factors such as increased awareness and screening procedures for diagnosis, a growing number of ADHD cases, progress in treatment methods, the evolution of healthcare infrastructure, and the broadening of health insurance coverage.
What Growth Rate Is Anticipated for the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market in the Coming Years?
The market size for therapeutics related to attention deficit hyperactivity disorder (ADHD) is forecasted to experience substantial growth in the coming years. By 2029, it is projected to reach $17.25 billion with a compound annual growth rate (CAGR) of 5.2%. The expected growth over the forecast period can be linked to advancements in genetic research and personalized medicine, rising awareness about mental health, international and national mental health campaigns, development of telehealth, and incorporation of behavioral therapies. The key trends during this forecast period comprise of technological enhancements in treatment, research and development efforts, incorporation of digital therapeutics, precision medicine strategies, and drug delivery system innovations.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14042&type=smp
Who Are the Leading Companies in the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?
Major companies operating in the attention deficit hyperactivity disorder (ADHD) therapeutics market are Pfizer Inc., Johnson And Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical’s, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., UCB S.A., Amneal Pharmaceuticals LLC, Lupin Ltd., Mallinckrodt Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co. Inc., Purdue Pharma L.P., Arbor Pharmaceuticals LLC, Tris Pharma Inc., NEOS Therapeutic Inc., Concert Pharmaceuticals Inc., Vayarin AG, Rhodes Pharmaceuticals L.P., KemPharm Inc., Impax Laboratories Inc., Aevi Genomic Medicine, Adlon Therapeutics L.P., Ironshore Pharmaceuticals Inc., Highland Therapeutics Inc.
What Are the Key Drivers of the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?
The escalating occurrence of attention-deficit hyperactivity disorder is predicted to foster expansion of the ADHD therapeutics market in the future. This surge in ADHD occurrence alludes to an ascending count of people being diagnosed with this neurodevelopmental disorder over time. Therapies for ADHD strive to address the diverse aspects of this condition, focusing on improved management of symptoms, functional disability, life quality, and overall well-being for those afflicted with ADHD. For instance, the Guardian, a US-based news company reported in January 2023 that an estimated 170,000 recognized patients were prescribed ADHD treatment in 2022, marking a 20.4% growth from the 141,000 recognized patients during the equivalent period in 2021. Thus, the burgeoning prevalence of ADHD is contributing to the advancement of the ADHD therapeutics market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=14042&type=smp
What Are the Key Market Segments in the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Industry?
The attention deficit hyperactivity disorder (ADHD) therapeutics market covered in this report is segmented –
1) By Drug Type: Stimulants, Non-Stimulants
2) By Psychotherapy: Behavior Therapy, Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Family Therapy
3) By Age Group: Pediatric And Adolescent, Adult
4) By Distribution Channel: Hospital Pharmacies, Specialty Clinics, Retail Pharmacies, E-Commerce
Subsegments:
1) By Stimulants: Amphetamine-Based Stimulants, Methylphenidate-Based Stimulants
2) By Non-Stimulants: Atomoxetine, Guanfacine, Clonidine
What Are the Latest Trends in the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?
Leading businesses in the attention-deficit hyperactivity disorder (ADHD) therapeutics market are focusing their efforts on creating digital enhancements such as Endeavor over-the-counter (OTC) versions of digital treatments for ADHD. This is in response to the growing demand for digital solutions as well as an increase in remote healthcare needs. Digital treatments, backed by evidence, use high-quality software programs to prevent, manage or cure a medical disorder. These treatments are developed to be utilized alone or alongside conventional medical treatments. For example, Akili, a digital health company from the US, launched an OTC version of its video game-based digital therapeutic for adults with ADHD in June 2023. Named EndeavorOTC, it was created to improve attention, time management, and organizational skills. This is a follow-up to Akili’s successful FDA-authorized prescription video game treatment, the EndeavorRx, for children with ADHD. The EndeavorOTC provides a non-pharmaceutical treatment option for adults battling ADHD symptoms.
Access The Full Report Here:
What Are the Key Regional Markets in the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Industry?
North America was the largest region in the attention deficit hyperactivity disorder (ADHD) therapeutic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the attention deficit hyperactivity disorder (ADHD) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14042
This Report Delivers Insight On:
1. How big is the attention deficit hyperactivity disorder (adhd) therapeutics market, and how is it changing globally?
2. Who are the major companies in the attention deficit hyperactivity disorder (adhd) therapeutics market, and how are they performing?
3. What are the key opportunities and risks in the attention deficit hyperactivity disorder (adhd) therapeutics market right now?
4. Which products or customer segments are growing the most in the attention deficit hyperactivity disorder (adhd) therapeutics market?
5. What factors are helping or slowing down the growth of the attention deficit hyperactivity disorder (adhd) therapeutics market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
